<DOC>
	<DOCNO>NCT01006096</DOCNO>
	<brief_summary>The purpose study determine whether erlotinib effective treatment psoriasis .</brief_summary>
	<brief_title>Erlotinib Treatment Psoriasis</brief_title>
	<detailed_description>Psoriasis vulgaris disease affect 25 million people North America Europe . It often present late adolescence usually persist life . Current therapy target specific immune molecule implicate cause disease . For example , biologic agent use severe psoriasis aim inflammatory mediator . These therapy prove effective also limitation .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Clinical diagnosis moderate severe psoriasis Must document moderate severe psoriasis Physician 's Global Assessment ( PGA ) Psoriasis Area Severity Index ( PASI ) Must able swallow tablet Must able provide write informed consent Subjects reproductive potential ( menopausal less 1 year surgically sterilize ) must practice effective contraceptive measure throughout study thirty day discontinuation study drug . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior randomization . Use concurrent agents/therapies psoriasis Bilirubin &gt; 3 X â‰¥ ULN moderate severe hepatic impairment Pregnant breastfeeding female Subjects currently receive anticancer treatment Subjects currently receive biologic treatment Subjects currently receive blood thinner ( warfarin heparin ) Subjects currently smoke Subjects skin disease opinion investigator , would inhibit ability use PGA PASI evaluation method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>double-blind</keyword>
	<keyword>randomize</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>erlotinib</keyword>
	<keyword>efficacy</keyword>
</DOC>